References on the Administration of Agents to Nude Mice Using
ALZET^® Osmotic Pumps

P8846 Dikmen,Z.G., Gellert,G.C., Dogan,P., Yoon,H., Lee,Y.B., Ahn,C.H., Shay,J.W. In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. Journal of Cellular Biochemistry 2008; 104(-3-):985-994. >>> RX-0047; oligonucleotide, phosphorothioate antisense; SC; IP; Mice (nude); 1002; 14 days; Controls received no treatment; comparison of IP injections vs. mp; antisense (HIF-1a); cancer (lung, prostate); animal info (Nu/Nu).

P8818 Conigliaro,A., Colletti,M., Cicchini,C., Guerra,M.T., Manfredini,R., Zini,R., Bordoni,V., Siepi,F., Leopizzi,M., Tripodi,M., Amicone,L. Isolation and characterization of a murine resident liver stem cell. CELL DEATH AND DIFFERENTIATION 2008; 15(-1-):123-133. >>> Fibroblast growth factor, bovine; Heparin; SC; Mice (nude); 10 days; Peptides.

P8817 Dings,R.P.M., Van Laar,E.S., Webber,J., Zhang,Y., Griffin,R.J., Waters,S.J., MacDonald,J.R., Mayo,K.H. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Letters 2008; 265(-2-):270-280. >>> Anginex; anginex topomimetic 0118; SC; Mice (nude); 28 days; Cancer (ovarian carcinoma); animal info (female, athymic nu/nu, 5-6 wks old); antiangiogenic.

P8815 Jin,H.K., Yang,R.H., Zheng,Z., Romero,M., Ross,J., Bou-Reslan,H., Carano,R.A.D., Kasman,I., Mai,E., Young,J., Zha,J.P., Zhang,Z.M., Ross,S., Schwall,R., Colbern,G., Merchant,M. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Research 2008; 68(-11-):4360-4368. >>> Hepatocyte growth factor, human; Dextran sulfate; IP; Mice (nude); 1002; ; Controls received mp w/ vehicle; functionality of mp verified by human HGF serum levels; long-term study; pumps replaced every 12 to 14 days; cancer (pancreatic); peptides; animal info (female, nu/nu).

P8791 Song,P.F., Sekhon,H.S., Fu,X.W., Maier,M., Jia,Y.B., Duan,J., Proskosil,B.J., Gravett,C., Lindstrom,J., Mark,G.P., Saha,S., Spindel,E.R. Activated cholinergic signaling provides a target in squamous cell lung carcinoma. Cancer Research 2008; 68(-12-):4693-4700. >>> Darifenacin; DMSO; PBS; SC; Mice (nude); 2004; 4 weeks; Controls received mp w/ vehicle; cancer (lung carcinoma); animal info (male, nu/nu); 50% DMSO; M3 mAChR antagonist.

P8437 Henke,E., Perk,J., Vider,J., de Candia,P., Chin,Y., Solit,D.B., Ponomarev,V., Cartegni,L., Manova,K., Rosen,N., Benezra,R. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. NATURE BIOTECHNOLOGY 2008; 26(-1-):91-100. >>> Oligonucleotide, antisense, peptide conjugated; oligonucleotide, phosphorothioate antisense; peptide, F3; TBS; SC; Mice (nude); mice; 1007D; 1002; 14, 21 days; Controls received mp w/ vehicle or control peptide and oligo in non-conjugated form, or rcId1-PCAO; comparison of IV injections vs. mp; pumps replaced after 14 days; no stress (see pg. 95, 97); stability verified after 24 hours in 37 C, plasma up to 28 days in 37 C saline; antisense (Id1, rcId1); cancer (breast, lung carcinoma); peptides; toxicology; animal info (female, nude NCR; male, C57J/B6); antisense oligos covalently coupled to address peptide that targets tumor endothelial cells; "no adverse effects on treated mice have been observed." (p. 97).

P8729 Masunaga,S., Takahashi,A., Ohnishi,K., Nagata,K., Suzuki,M., Kashino,G., Kinashi,Y., Ohnishi,T., Ono,K. Dependency of repair of radiation-induced damage on p53 status and efficient inhibition of the repair with wortmannin treatment in vivo, with reference to the effect on intratumor quiescent cell population. Oncology Reports 2007; 18(-6-):1589-1596. >>> Uridine, bromodeoxy; Saline; SC; Mice (nude); 2001; 7 days; Tissue perfusion (tumor); cancer; animal info (Balb/cA, nude); labeling of tumor cells.

P8704 Tummalapalli,P., Spomar,D., Gondi,C.S., Olivero,W.C., Gujrati,M., Dinh,D.H., Rao,J.S. RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. INTERNATIONAL JOURNAL OF ONCOLOGY 2007; 31(-5-):1039-1050. >>> RNA, small interfering; Mice (nude); 3-4 weeks; Controls received no treatment; cancer (meningioma); animal info (athymic, nude); siRNA plasmid vectors targeting cathepsin B and matrix metalloproteinase MMP9.

P8520 Kumar,R., Knick,V.B., Rudolph,S.K., Johnson,J.H., Crosby,R.M., Crouthamel,M.C., Hopper,T.M., Miller,C.G., Harrington,L.E., Onori,J.A., Mullin,R.J., Gilmer,T.M., Truesdale,A.T., Epperly,A.H., Boloor,A., Stafford,J.A., Luttrell,D.K., Cheung,M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. MOLECULAR CANCER THERAPEUTICS 2007; 6(-7-):2012-2021. >>> GW771806; SC; Mice (nude); mice (SCID); 2001; 5,6,21 days; Controls received mp w/ vehicle; dose-response (fig. 4); comparison of oral gavage vs. mp; cancer (colon); animal info (female, Swiss nu/nu, 8-12 weeks old); VEGFR inhibitor; "Continuous infusion of VEGFR inhibitor is more effective in controlling tumor growth and angiogenesis than p.o bolus dosing." (p. 2018).

P8514 Ishikawa,M., Kitayama,J., Yamauchi,T., Kadowaki,T., Maki,T., Miyato,H., Yamashita,H., Nagawa,H. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. CANCER SCIENCE 2007; 98(-7-):1120-1127. >>> Adiponectin, recomb. mouse; PBS; IP; Mice (nude); 2004; 14 days; Controls received mp w/ vehicle; comparison of intratumoral injections vs. mp; no stress (see pg. 1124); cancer (gastric); peptides; animal info (female, BALB/c, nude, 5 weeks old); "Continuous adiponectin infusion into the peritoneal cavity caused significant antitumor effects." (p. 1126); "The intraperitoneal infusion did not cause apparent side effects with no significant change of total weight." (p. 1124).

P8489 Song,P., Sekhon,H.S., Lu,A., Arredondo,J., Sauer,D., Gravett,C., Mark,G.P., Grando,S.A., Spindel,E.R. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma growth and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Cancer Research 2007; 67(-8-):3936-3944. >>> Darifenacin; DMSO; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; plasma levels taken; dose-response (p. 3941); cancer (lung); tumors implanted in right flank; M3 receptor antagonist; xenograft; animal info (6-7 weeks old).

P8467 Zhang,Y.M., Bressler,J.P., Neal,J., Lal,B., Bhang,H.E.C., Laterra,J., Pomper,M.G. ABCG2/BCRP expression modulates D-luciferin-based bioluminescence imaging. Cancer Research 2007; 67(-19-):9389-9397. >>> Luciferin; SC; Mice (nude); 1007D; 1 hour; Cancer; bioluminescence imaging (BLI); animal info (female, nude); tumor cells injected SC; pg 939s shows images with pumps implanted.

P8456 Garbaccio,R.M., Tasbera,E.S., Neilson,L.A., Coleman,P.J., Fraley,M.E., Olson,C., Bergman,J., Torrent,M., Buser,C.A., Rickert,K., Walsh,E.S., Hamilton,K., Lobell,R.B., Tao,W.K., South,V.J., Diehl,R.E., Davide,J.P., Yan,Y.W., Kuo,L.C., Li,C.Z., Prueksaritanont,T., Fernandez-Metzler,C., Mahan,E.A., Slaughter,D.E., Salata,J.J., Kohl,N.E., Huber,H.E., Hartman,G.D. Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP. BIOORGANIC&MEDICINAL CHEMISTRY LETTERS 2007; 17(-20-):5671-5676. >>> Kinesin spindle protein inhibitor; SC; Mice (nude); 2001D; 22-24 hours; Cancer (ovarian carcinoma); animal info (athymic nude).

P8305 Mook,O.R., Baas,F., de Wissel,M.B., Fluiter,K. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. MOLECULAR CANCER THERAPEUTICS 2007; 6(-3-):833-843. >>> RNA, small interfering; RNA, small interfering, LNA-modified; Radio-isotopes, 3H-; SC; Mice (nude); 1007D; 7 days; 48 hours; Controls received mp w/ mismatch siRNA or saline; comparison of IV injections vs. mp; stability verified by incubation in mouse serum; half-life (p. 837) increased in LNA-modified; unmodified completely degraded in<5 hours; cancer (pancreatic); animal info (NMRI nu/nu, 8-10 weeks old); siRNA against RNA polymerase II, enhanced GFP, or mismatch.

P8226 Michaud-Levesque,J., Demeule,M., Beliveau,R. In vivo inhibition of angiogenesis by a soluble form of melanotransferrin. Carcinogenesis 2007; 28(-2-):280-288. >>> Melanotransferrin, soluble, truncated recomb. human; melanotransferrin, [125I]-soluble, truncated recomb. human; Ringers's solution; HEPES solution; SC; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; dose-response (fig. 6); comparison of SC injections vs. mp; half-life (p. 285) ~7.6 hours + or - 0.9 hours; cancer; peptides; animal info (female, athymic CD-1-nuBr, 5-10 weeks old); "The use of ALZET osmotic pump infusion technique provided a higher therapeutic efficacy as compared with repeated S.C. injections, emphasizing the advantages of constant infusion rather than pulse-dose drug inputs for antiangiogenic effects." (p. 287).

P8224 Menon,J., Soto-Pantoja,D.R., Callahan,M.F., Cline,J.M., Ferrario,C.M., Tallant,E.A., Gallagher,P.E. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Research 2007; 67(-6-):2809-2815. >>> Angiotensin (1-7); Saline; heparin; IV (jugular); Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; no stress (see pg. 2810); cancer (lung); peptides; animal info (male, athymic, 2-4 weeks old, 15-20 grams); "During the infusion period, the animals maintained their body weight as well as food and water consumption and showed no evidence of reduced motor function. Additionally, no gross pathological abnormalities were observed in major organs..indicating a lack of toxic side effects." (p. 2810).

P8066 Bielinska,M., Seehra,A., Toppari,J., Heikinheimo,M., Wilson,D.B. GATA-4 is required for sex steroidogenic cell development in the fetal mouse. Developmental Dynamics 2007; 236(-1-):203-213. >>> Luteinizing hormone releasing hormone, [D-Trp6]-; SC; Mice (nude); 3 weeks; Replacement therapy (gonadectomy); peptides; animal info (female, NU/J, chimeric teratoma).

P8016 Fridman,J.S., Caulder,E., Hansbury,M., Liu,X.D., Yang,G.J., Wang,Q., Lo,Y., Zhou,B.B., Pan,M., Thomas,S.M., Grandis,J.R., Zhuo,J.C., Yao,W.Q., Newton,R.C., Friedman,S.M., Scherle,P.A., Vaddi,K. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clinical Cancer Research 2007; 13(-6-):1892-1902. >>> Marimastat; INCB3619; SC; Mice; mice (nude); 7, 14 days; Controls received mp w/ vehicle; enzyme inhibitor (metalloprotease); cancer (squamous cell carcinoma, breast, lung carcinoma); toxicology; animal info (BALB/c, CD-1 nu/nu); ErbB ligand shedding inhibitor.

R0238 Boeckle,S., Wagner,E. Optimizing targeted gene delivery: Chemical modification of viral vectors and synthesis of artificial virus vector systems. AAPS Journal 2006; 8(-4-):E731-E742. >>> Virus, synthetic RNA; Intratumoral; Mice (nude); ; Cancer (glioblastoma); "Control animals within 30 days after tumor implantation, all treated animals survived for >1 year and were completely cured." (p. E738).

P8294 Yagi,H., Ueda,M., Jinno,H., Aiura,K., Mikami,S., Tada,H., Seno,M., Yamada,H., Kitajima,M. Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties. CANCER SCIENCE 2006; 97(-12-):1315-1320. >>> Fibroblast growth factor, basic; CL-RFN89; PBS; Mice (nude); ; Cancer (carcinoma); animal info (4 weeks old, female, Balb/C, nude); antiangiogenesis; tumor cells in right flank, agent is an insertional-fusion protein.

P8286 Ying,H., Biroc,S.L., Li,W.W., Alicke,B., Xuan,J.A., Pagila,R., Ohashi,Y., Okada,T., Kamata,Y., Dinter,H. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. MOLECULAR CANCER THERAPEUTICS 2006; 5(-9-):2158-2164. >>> Fasudil; Saline; SC; Mice (nude); 21 days; Controls received mp w/ vehicle; cancer (lung).

P8208 Martens,T., Schmidt,N.O., Eckerich,C., Fillbrandt,R., Merchant,M., Schwall,R., Westphal,M., Lamszus,K. A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clinical Cancer Research 2006; 12(-20-):6144-6152. >>> Antibody, anti-c-Met, OA5D5; Histidine; CSF/CNS (intratumoral); Mice (nude); 2004; 12, 21, 28 days; Controls received mp w/ vehicle; cancer (glioblastoma); ALZET brain infusion kit 2 used; animal info (male, NMRI-nu/nu, 6-8 wks old); "Because the OA-5D5 antibody is a relatively large but stable molecule, convection-enhanced drug delivery (by mp) was ideally suited to deliver it in our orthotopic model." (p.6151); tissue perfusion (tumor).

P8169 Masunaga,S.I., Uto,Y., Nagasawa,H., Hori,H., Nagata,K., Suzuki,M., Kinashi,Y., Ono,K. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. dependency on p53 status of tumor cells and the effects on intratumor quiescent cells. Anticancer Research 2006; 26(-2A-):1261-1270. >>> Uridine, bromodeoxy, 5-; Saline, physiological; SC; Mice (nude); 5, 7 days; Cancer (squamous cell carcinoma); animal info (BALB/cA, C3H/He, 6-7 weeks old, 22 grams); labeling of tumor 'P' cells.

P8140 Husen,B., Huhtinen,K., Saloniemi,T., Messinger,J., Thole,H.H., Poutanen,M. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 2006; 147(-11-):5333-5339. >>> B10721325; estrone; DMSO; propanediol; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (p.5335); pumps replaced after 14 days; enzyme inhibitor (hydroxysteroid 17 beta dehydrogenase 1); cancer (breast); animal info (female, BALB/cA Bom-v, Crl: nu/nu, 10-11 wks old); 50%DMSO; endocrinology.

P8121 Fujii,T., Yonemitsu,Y., Onimaru,M., Tanii,M., Nakano,T., Egashira,K., Takehara,T., Inoue,M., Hasegawa,M., Kuwano,H., Sueishi,K. Nonendothelial mesenchymal cell-derived MCP-1 is required for FGF-2- mediated therapeutic neovascularization - Critical role of the inflammatory/arteriogenic pathway. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 2006; 26(-11-):2483-2489. >>> Antibody, anti-VEGF; IP; Mice (nude); 1007D; ; Controls received mp w/ IgG; cardiovascular; ischemia (hind limb); animal info (male, C57BL/6, 6-7 wk. old; Balb/c nu/nu, 5 wk. old; C57BL/6, CCR2-/-).

P8018 Kim,K.S., Sengupta,S., Berk,M., Kwak,Y.G., Escobar,P.F., Belinson,J., Mok,S.C., Xu,Y. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Research 2006; 66(-16-):7983-7990. >>> Lysophosphatidic acid; PBS; IP; Mice (nude); 1002; 21 days; Controls received mp w/ vehicle; pumps replaced every 15 days; cancer (ovarian carcinoma); animal info (female, nu/nu, skov3 tumors placed on ovaries); mp siliconized by placing 100 ul sigmacote into mp, removing liquid and letting the mp dry before agent is introduced; developed mouse model of metastatic ovarian cancer.

P7999 Ueda,S., Nakamura,T., Yamada,A., Teratani,A., Matsui,N., Furukawa,S., Hoshino,Y., Narita,M., Yodoi,J., Nakamura,H. Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. LIFE SCIENCES 2006; 79(-12-):1170-1177. >>> Thioredoxin, human recomb.; SC; Mice (nude); 2002; 2 weeks; Controls received mp w/ PBS; plasma levels taken; cancer (colon, carcinoma); peptides; animal info (female, 6 weeks old, nude); xenograft.

P7922 Segrelles,C., Moral,M., Lara,M.F., Ruiz,S., Santos,M., Leis,H., Garcia-Escudero,R., Martinez-Cruz,A.B., Martinez-Palacio,J., Hernandez,P., Ballestin,C., Paramio,J.M. Molecular determinants of Akt-induced keratinocyte transformation. ONCOGENE 2006; 25(-8-):1174-1185. >>> Rapamycin; PBS; BSA; SC; Mice (nude); 2002; 2 weeks; Cancer; animal info (nude, 5-6 weeks old, female).

P7902 Husen,B., Huhtinen,K., Poutanen,M., Kangas,L., Messinger,J., Thole,H. Evaluation of inhibitors for 17 beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. MOLECULAR AND CELLULAR ENDOCRINOLOGY 2006; 248(-1-2-):109-113. >>> Estrone; B10720512; B10721325; B10720440; B10720511; B10715817; DMSO; propanediol; SC; Mice (nude); 1002; 4 weeks; 14 days; Controls received mp w/ vehicle; replacement therapy (ovariectomy); dose-response (fig. 5); pumps replaced after 2 weeks; enzyme inhibitor (17 beta-hydroxysteroid dehydrogenase); cancer (breast carcinoma); animal info (female, Crl: NU/NU, 10-11 wk old); 50% DMSO.

P7877 Kaneko,H., Kikuchi,K., Noguchi,J., Ozawa,M., Ohnuma,K., Maedomari,N., Kashiwazaki,N. Effects of gonadotrophin treatments on meiotic and developmental competence of oocytes in porcine primordial follicles following xenografting to nude mice. REPRODUCTION 2006; 131(-2-):279-288. >>> Follicle-stimulating hormone, porcine; Saline; SC; Mice (nude); 2004; 7, 14 days; Controls received no hormone treatment; replacement therapy (ovariectomy); dose-response (pg. 280); animal info (female, Crlj: CD1-Foxn1nu, 5-6 wk old); ovarian xenografts.

P7807 Jung,F.H., Pasquet,G., Lambert-van der Brempt,C., Lohmann,J.J.M., Warin,N., Renaud,F., Germain,H., De Savi,C., Roberts,N., Johnson,T., Dousson,C., Hill,G.B., Mortlock,A.A., Heron,N., Wilkinson,R.W., Wedge,S.R., Heaton,S.P., Odedra,R., Keen,N.J., Green,S., Brown,E., Thompson,K., Brightwell,S. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. Journal of Medicinal Chemistry 2006; 49(-3-):955-970. >>> Thiazoloquinazoline, compound 54; Tris buffer; SC; Mice (nude); 2001D; 48 hours; Controls received mp w/ vehicle; half-life (pg. 963) 0.7 hours in mouse plasma; enzyme inhibitor (aurora A/B kinase); cancer (colorectal carcinoma); animal info (Swiss nu/nu, male, 8-10 wk old).

P7800 Palm,D., Lang,K., Niggemann,B., Drell,T.L., Masur,K., Zaenker,K.S., Entschladen,F. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by betablockers. International Journal of Cancer 2006; 118(-11-):2744-2749. >>> Norepinephrine; propranolol; Saline, physiological; ascorbic acid; SC; Mice (nude); 1002; 4 weeks; Controls received mp w/ vehicle; pumps replaced after 2 weeks; half-life (pg. 2745) short, quickly metabolized; cancer (prostate carcinoma); animal info (female, BALB/C nude, athymic, 6 wk. old, 15g.).

P7748 Huang,X.L., Brown,C., Ni,W.H., Maynard,E., Rigby,A.C., Oettgen,P. Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood 2006; 107(-8-):3153-3160. >>> Peptide A1; peptide A1, mutant; PBS; SC; Mice (nude); 10,14 days; Controls received mp w/ vehicle; no stress (see pg. 3157); cancer (B16 melanoma); peptides; animal info (C57BL/6, female); peptide A1 is composed of ETS sequences and a 12-amino acid HIV-TAT protein-transducing membrane peptide.

P7694 Michl,J., Scharf,B., Schmidt,A., Huynh,C. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. International Journal of Cancer 2006; 119(-7-):1577-1585. >>> PNC-28; PBS, sterile; SC; IP; Mice (nude); 1002; 2 weeks; Controls received mp w/ control peptide; cancer (pancreatic); peptides; animal info (Nu/Nu, 7-8 weeks old, 22-24 g); xenotransplant tumor cells in hindleg or IP; additional mice had IP pumps; "...PNC-28 may be effective in treating cancers especially if delivered directly to the tumor." (p. 1577).

P7623 Ohyama,M., Terunuma,A., Tock,C.L., Radonovich,M.F., Pise-Masison,C.A., Hopping,S.B., Brady,J.N., Udey,M.C., Vogel,J.C. Characterization and isolation of stem cell-enriched human hair follicle bulge cells. Journal of Clinical Investigation 2006; 116(-1-):249-260. >>> Uridine, bromodeoxy-; SC; Mice (nude); 1002; 4-6 weeks; Pumps replaced every 2 weeks; multiple pumps per animal (2).

P8287 Manabe,T., Okino,H., Maeyama,R., Mizumoto,K., Tanaka,M., Matsuda,T. New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: Potential use for suppression of local recurrence of pancreatic cancer. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS 2005; 73B(-1-):203-207. >>> Gemcitabine; SC; Mice (nude); 1007D; 7 days; Tissue perfusion (intratumoral); comparison of IP injections; cancer (pancreatic); animal info (five week old); pump used as part of a novel infusion device; pictures of device p. 205; PE tubing used to connect pump to perfusion device; continuous infusion resulted in macroscopically undetectable tumors after day 6.

P8162 Tjomsland,V., El-Salhy,M. Anti-tumour effects of triple therapy with octreotide, galanin and serotonin in comparison with those of 5-fluorouracil/leukovorin on human colon cancer. INTERNATIONAL JOURNAL OF ONCOLOGY 2005; 27(-2-):427-432. >>> Octreotide; galanin, synthetic human; serotonin; IP; Mice (nude); 1002; 14 days; No stress (see pg. 429); cancer (colon); animal info (female, BALB/cA-nu, 6-8 weeks old, 20 grams); "The animals treated with triple therapy (mp) did not show any sign of discomfort or suffering during the experiment and held a stable body weight." (p. 429).

P7774 Saba,S.R., Garces,A.H., Clark,L.C., Soto,J., Gower,WR Jr, Vesely,D.L. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas. JOURNAL OF HISTOCHEMISTRY&CYTOCHEMISTRY 2005; 53(-8-):989-995. >>> Atrial natriuretic peptide; vessel dilataor peptide; kaliuretic peptide; natriuretic peptide, long-acting; Mice (nude); 2004; 4 weeks; Cancer (panceatic adenocarcinoma); peptides; animal info (athymic).

P7764 Pukac,L., Kanakaraj,P., Humphreys,R., Alderson,R., Bloom,M., Sung,C., Riccobene,T., Johnson,R., Fiscella,M., Mahoney,A., Carrell,J., Boyd,E., Yao,X.T., Zhang,L., Zhong,L., von Kerczek,A., Shepard,L., Vaughan,T., Edwards,B., Dobson,C., Salcedo,T., Albert,V. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. British Journal of Cancer 2005; 92(-8-):1430-1441. >>> Fluorouracil, 5-; SC; Mice (nude); 2002; 14 days; Controls received no treatment; cancer (colon); animal info (female, Swiss, athymic, 7-8 wk old, 20g.).

P7612 Gupta,A.K., Cerniglia,G.J., Mick,R., McKenna,W.G., Muschel,R.J. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Research 2005; 65(-18-):8256-8265. >>> Amprenavir; SC; Mice (nude); 1-4, 2-15 days; Controls received mp w/ vehicle; functionality of mp verified by serum drug levels by HPLC; no stress (see pg.826); enzyme inhibitor (HIV protease); cancer (SQ208, head and neck, T24 bladder); animal info (female, Ncr- nu/nu); irradiation.

P7505 Belvisi,L., Riccioni,T., Marcellini,M., Vesci,L., Chiarucci,I., Efrati,D., Potenza,D., Scolastico,C., Manzoni,L., Lombardo,K., Stasi,M.A., Orlandi,A., Ciucci,A., Nico,B., Ribatti,D., Giannini,G., Presta,M., Carminati,P., Pisano,C. Biological and molecular properties of a new alphav beta3/alphav beta5 integrin antagonist. MOLECULAR CANCER THERAPEUTICS 2005; 4(-11-):1670-1680. >>> ST1646; Saline; SC; Mice (nude); 2002; 14 days; Controls received mp w/ vehicle; animal info (CD1); tumor cells were placed SC in the right flank, while the pump was placed SC in the left flank; ST1646 delivery via an osmotic pump inhibited the growth and vascularization of tumor xenografts originating from the injection of alpha v beta 3 alpha v beta 5-expressing human ovarian carcinoma cells in nude mice.

P7434 Kawakami,K., Kioi,M., Liu,Q., Kawakami,M., Puri,R.K. Evidence that IL-13R alpha-2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. Journal of Immunotherapy 2005; 28(-3-):193-202. >>> Interleukin-13-PE38; interleukin-13Ra2, pME18S-; CSF/CNS (intratumoral); Mice (nude); 1003D; 1007D; 7 days; Controls received mp w/ vehicle or antisense IL-13Ra2 plasmid vector; pumps replaced after 3 days; cancer (glioblastoma); cyanoacrylate adhesive; convection enhanced delivery; IL-13Ra2 cDNA encoding plasmid vector; "the upregulated IL-13 Ra2 chain was successfully targeted with a continuous infusion of IL-13 cytotoxin." (p. 199).

P7388 Arcella,A., Carpinelli,G., Battaglia,G., D'Onofrio,M., Santoro,F., Ngomba,R.T., Bruno,V., Casolini,P., Giangaspero,F., Nicoletti,F. Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. NEURO-ONCOLOGY 2005; 7(-3-):236-245. >>> LY341495; ethylglutamate, alpha-25; Saline; SC; Mice (nude); 1007D; 2004; 7, 28 days; Controls received mp w/ vehicle; cancer (glioma); mGlu 2/3 receptor antagonist; pumps removed prior to MRI.

P7326 Kishore,R., Qin,G.J., Luedemann,C., Bord,E., Hanley,A., Silver,M., Gavin,M., Goukassain,D., Losordo,D.W. The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A. Journal of Clinical Investigation 2005; 115(-7-):1785-1796. >>> Uridine, bromodeoxy-; Mice (nude); 7 days; Cardiovascular; ischemia (hindlimb); labeling of ischemic hind limb muscle.

P7322 Dings,R.P.M., Williams,B.W., Song,C.W., Griffioen,A.W., Mayo,K.H., Griffin,R.J. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. International Journal of Cancer 2005; 115(-2-):312-319. >>> Anginex; PBS; SC; Mice (nude); 2002; 2004; 2, 4 weeks; Controls received mp w/ vehicle; comparison of IP injections vs. mp; no stress (see pg. 315); half-life (p. 318) 50-90 min. in mice; cancer (ovarian, mammary carcinoma); toxicology; peptides; irradiation 5 Gy once per week or 25 Gy one time tumo-bearing legs; angiogenesis inhibitor; "continuous infusion of anginex in combination with weekly irradiation resulted in tumor regression and impalpable tumors by the end of treatment." P317.

P7321 Aparicio,T., Kotelevets,L., Tsocas,A., Laigneau,J.P., Sobhani,I., Chastre,E., Lehy,T. Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in ApcMin/+ mice. Gut 2005; 54(-8-):1136-1145. >>> Leptin, recomb. human; leptin, recomb. murine; Saline, BSA; SC; Mice (nude); mice; 2002; 4, 6 weeks; Controls received mp w/ vehicle; functionality of mp verified by plasma leptin levels; pumps replaced every 2 weeks; cancer (colon, intestinal adenoma); peptides.

P7267 Fluiter,K., Frieden,M., Vreijling,J., Rosenbohm,C., de Wissel,M.B., Christensen,S.M., Koch,T., Orum,H., Baas,F. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. CHEMBIOCHEM 2005; 6(-6-):1104-1109. >>> Oligodeoxynucleotide, antisense; oligodeoxynucleotide, amino-LNA antisense; oligodeoxynucleotide, thio-LNA antisense; oligodeoxynucleotide, LNA antisense; oligodeoxynucleotide, missense; SC; Mice (nude); 1002; 11 days; 48 hours; Controls received mp w/ saline; dose-response (fig. 4); no stress (see pg. 1106); stability verified by incubation in human serum; antisense (H-Ras); cancer (prostate).

P7248 Lakka,S.S., Gondi,C.S., Dinh,D.H., Olivero,W.C., Gujrati,M., Rao,V.H., Sioka,C., Rao,J.S. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. Journal of Biological Chemistry 2005; 280(-23-):21882-21892. >>> RNA, small interfering; RNA, small interfering, uPAR; RNA, small interfering, MMP-9; CSF/CNS; Mice (nude); 1002; 2 weeks; Controls received mp w/ PBS or empty vector; cancer (glioblastoma); siRNA is within a plasmid vector (pUM vector); antiangiogenesis; gene therapy.

P7136 Bandyopadhyay,A., Wang,L., Loepz-Casillas,F., Mendoza,V., Yeh,I.T., Sun,L.Z. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. PROSTATE 2005; 63(-1-):81-90. >>> Transforming growth factor-B3 receptor, recomb. soluble; PBS; SC; Mice (nude); 2002; 14 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; no stress (see pg. 84,88); cancer (prostate); multiple pumps per animal (2).

P7022 Shi,Y.Q., Wu,J.M., Mick,R., Cerniglia,G.J., Cohen-Jonathan,E., Rhim,J.S., Koch,C.J., Bernhard,E.J. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival. PROSTATE 2005; 62(-1-):69-82. >>> L-744832; L-788123; DMSO; water, sterile distilled; SC; Mice (nude); 1007D; 3,7 days; Controls received mp w/ vehicle; enzyme inhibitor (farnesyltransferase); cancer (prostate); 50% DMSO; tumor irridiated on day 3.

P6942 El-Salhy,M. Effects of triple therapy with octreotide, galanin and serotonin on a human colon cancer cell line. Oncology Reports 2005; 13(-1-):45-49. >>> Octreotide; galanin; serotonin; Saline; IP; Mice (nude); 1002; 14 days; Controls received mp w/ vehicle; cancer (colon).

P6928 El-Salhy,M. Effects of triple therapy with octreotide, galanin and serotonin on a human colon cancer cell line implanted in mice: comparison between different routes of administration. Histology and Histopathology 2005; 20(-1-):19-25. >>> Octreotide; galanin; serotonin; Saline; SC; IP; Mice (nude); 1002; 14 days; Controls received mp w/ vehicle; comparison of IP injections vs. IP mp; cancer (colon); "continuous i.p infusion appears, however to be the most effective route of administration." (p. 19,25).

P7098 Kawakami,K., Kawakami,M., Puri,R.K. Nitric oxide accelerates interleukin-13 cytotoxin-mediated regression in head and neck cancer animal model. Clinical Cancer Research 2004; 10(-15-):5264-5270. >>> MLA; IP; Mice (nude); 1007D; 7 days; Cancer (head, neck); MLA is NW-monomethyl-L-arginine.

P7075 Thijssen,V.L.J.L., Brandwijk,R.J.M.G., Dings,R.P.M., Griffioen,A.W. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Experimental Cell Research 2004; 299(-2-):286-293. >>> Anginex; Saline; SC; Mice (nude); 2004; 20 days; Controls received mp w/ vehicle; cancer (melanoma, ovarian carcinoma).

P7065 Masunaga,S.I., Takahashi,A., Ohnishi,K., Ohnishi,T., Nagata,K., Suzuki,M., Kinashi,Y., Ono,K. Effects of mild temperature hyperthermia and p53 status on the size of hypoxic fractions in solid tumors, with reference to the effect in intratumor quiescent cell populations. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 2004; 60(-2-):570-577. >>> Uridine, bromodeoxy-; Saline, physiological; SC; Mice (nude); 2001; 7 days; Controls received no treatment; cancer (squamous cell carcinoma).

P7052 Alley,M.C., Hollingshead,M.G., Pacula-Cox,C.M., Wand,W.R., Hartley,J.A., Howard,P.W., Gregson,S.J., Thurston,D.E., Sausville,E.A. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations. Cancer Research 2004; 64(-18-):6700-6706. >>> SJG-136; DMSO; PEG; IV (jugular); Mice (nude); 2001; 5 days; Controls received mp w/ vehicle; comparison of IV injections vs. mp; no stress (see pg. 6706); cancer (melanoma); agent also known as NSC 694501; 50% DMSO; "It is noteworthy that 5-day continuous infusions are highly effective in the LOX IMVI tumor model...continuous infusions were highly active and the lower peak plasma concentrations afforded by them may render infusion a useful mode for SJG-136 delivery in man." (pg. 6704-5).

P7028 Harrington,K.J., Syrigos,K.N., Uster,P.S., Zetter,A., Lewanski,C.R., Gullick,W.J., Vile,R.G., Stewart,J.S.W. Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model. British Journal of Cancer 2004; 91(-2-):366-373. >>> Uridine, iododeoxy-; DMSO; water distilled; SC; Mice (nude); 2002; 7 days; Controls received PBS injections; comparison of pegylated liposomes vs. IV bolus injections vs. mp; no stress (pg. 370); cancer (head and neck); toxicology; 20% DMSO; therapeutic irradiation with 137Cs source after day 7.

P7005 Duncan,R.E., El-Sohemy,A., Archer,M.C. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. Journal of Biological Chemistry 2004; 279(-32-):33079-33084. >>> Mevalonate; SC; Mice (nude); 2004; 13 weeks; Controls received mp w/ vehicle, or isotonic saline; long-term study; pumps replaced every 28 days; cancer (MDA-MB-435); MDA-MB-435 is a highly malignant human cancer of either breast adenocarcinoma or occult melanoma (origin uncertain); cancer (breast, melanoma, adenocarcinoma).

P6923 Kawakami,K., Kawakami,M., Kioi,M., Husain,S.R., Puri,R.K. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. Journal of Neurosurgery 2004; 101(-6-):1004-1011. >>> Interleukin-13, PE38; Albumin, human serum; PBS; CSF/CNS; Mice (nude); 1007D; 7 days; Comparison of CNS injections vs. mp; cancer (glioma); ALZET brain infusion kit; cyanoacrylate adhesive.

P6814 Wang,Q.C., Horiatis,D., Pinski,J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. International Journal of Cancer 2004; 111(-4-):508-513. >>> Interleukin-6; SC; Mice (nude); 3 weeks; Controls received SC saline injections; comparison of SC injections vs. mp; no stress (see pg. 511); cancer (prostate).

P6790 Seo,Y., Yan,T., Schupp,J.E., Colussi,V., Taylor,K.L., Kinsella,T.J. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2-deoxyribose. Clinical Cancer Research 2004; 10(-22-):7520-7528. >>> Uridine, iododeoxy; NaOH; SC; Mice (nude); 2001; 7 days; Comparison of oral IPdR vs. mp; cancer (colon); athymic; "the use of oral IPdR results in dramatically higher but transient plasma IUdR levels in comparison with continuous infusion IUdR." (p. 7523).

P6774 Bello,L., Lucini,V., Costa,F., Pluderi,M., Giussani,C., Acerbi,F., Carrabba,G., Pannacci,M., Caronzolo,D., Grosso,S., Shinkaruk,S., Colleoni,F., Canron,X., Tomei,G., Deleris,G., Bikfalvi,A. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. Clinical Cancer Research 2004; 10(-13-):4527-4537. >>> PEX, recomb. human; PF-4/CTF; P4-4/DLR; vascular endothelial growth inhibitor, cyclo-; Water, sterile; SC; Mice; mice (nude); 2004; 28, 112, 140 days; Dose-response; long-term study; pumps replaced every 28 days; no stress (see pg. 4532); cancer (glioma); peptides; "The treatment was always very well tolerated without the occurrence of any side effects." (p. 4532); angiogenesis inhibitor.

P6720 Gondi,C.S., Lakka,S.S., Dinh,D.H., Olivero,W.C., Gujrati,M., Rao,J.S., Rao,J.S. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. ONCOGENE 2004; 23(--):8486-8496. >>> RNA, small interfering; EV/SV vector; PBS; CSF/CNS (intratumoral); Mice (nude); ; Controls received mp w/ vehicle; tissue perfusion (tumor); cancer (glioma); gene therapy; antiangiogenesis; siRNA (cathepsin B); pump model not stated (0.25 ul/hr); "...local intracranial delivery of pcu using mini-osmotic pumps effectively inhibited human malignant glioma growth.".

P6646 Aharinejad,S., Paulus,P., Sioud,M., Hofmann,M., Zins,K., Schaefer,R., Stanley,E.R., Abraham,D., Aharinejad,S. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Research 2004; 64(--):5378-5384. >>> Oligonucleotide, antisense; oligonucleotide, scrambled; Ringer's solution; SC; Mice (nude); 1002; 14 days; Controls received mp w/ vehicle; antisense (CSF)-1; cancer (carcinoma, breast); transplantation.

P6565 Morita,T., Shibata,K., Kikkawa,F., Kajiyama,H., Ino,K., Mizutani,S. Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo. International Journal of Cancer 2004; 109(-4-):525-532. >>> Oxytocin; IP; Mice (nude); 2002; 2 weeks; Controls received w/ physiological saline; no stress (see pg.530); cancer (ovarian carcinoma).

P6556 Nap,A.W., Griffioen,A.W., Dunselman,G.A.J., Bouma-Ter Steege,J.C.A., Thijssen,V.L.J.L., Evers,J.L.H., Groothuis,P.G. Antiangiogenesis therapy for endometriosis. Journal of Clinical Endocrinology and Metabolism 2004; 89(-3-):1089-1095. >>> Endostatin; anginex; SC; Mice (nude); 1002; 2 weeks; Controls received SC saline daily; no stress (see pg.1092); peptides; "The angiostatic agents did not appear to affect the overall health of the mice...The behavior of the mice during treatments was normal as well." (p. 1092).

P6537 McLaughlin,P.J., Stack,BC Jr, Braine,K.M., Ruda,J.D., Zagon,I.S. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: Dependency on the route of administration. INTERNATIONAL JOURNAL OF ONCOLOGY 2004; 24(-1-):227-232. >>> Enkephalin; Saline; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; OGF plasma levels taken; comparison of IP and intratumoral injections vs. SC mp; adverse reaction: (see pg. 229) "within 2 days...3 minipumps containing saline were spotaneously dislodged." [possible pocket too small]; cancer (carcinoma); peptides; enkephalin was met-5 and termed OGF or opioid growth factor.

P6344 El-Salhy,M., Dennerqvist,V. Effects of triple therapy with octreotide, galanin and serotonin on liver metastasis of human colon cancer in xenografts. Oncology Reports 2004; 11(--):1177-1182. >>> Octreotide; galanin; serotonin; Saline; IP; Mice (nude); 1002; 14 days; Controls received mp w/ vehicle; no stress (pg. 1179); cancer (colon).

P5950 Schmidt,N.O., Ziu,M., Carrabba,G., Giussani,C., Bello,L., Sun,Y.P., Schmidt,K., Albert,M., Black,P.M., Carroll,R.S. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clinical Cancer Research 2004; 10(-4-):1255-1262. >>> Endostatin, recomb. murine; PBS; CSF/CNS (intratumoral); Mice (nude); 2004; 21 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; comparison of SC injections vs. chronic ICV mp; no stress (see pg. 1261); cancer (glioma); ALZET brain infusion kit 1 used (per Dr. Carroll); MRI; "The direct infusion of therapeutic compounds into brain tumors can overcome some of the obstacles of drug delivery." p. 1255; BIK's removed prior to MRI; "no signs of intracranial bleeding due to the presence of the pumps or antiangiogenic treatment were observed..." (p. 1261); angiogenesis inhibitor; surgical glue used to affix cannula to the skull.

R0182 Mayo,K.H., Griffioen,A.W. Designing beta pep peptides: a rational approach to the discovery of n ovel pharmaceutical agents and small molecules. DRUGS OF THE FUTURE 2003; 28(-4-):337-346. >>> Anginex; PBS; SC; Mice (nude); 14,28 days; comparison of SC injections vs. mp; cancer (melanoma, colon, ovarian); peptides; angiogenesis inhibitor; "administration of anginex by osmotic mini-pumps gave the best results, compared to loco-regional injections, once-or-twice-daily subcutaneous injections or slow release alginate strategies." (p. 341).

P6636 Dings,R.P.M., van der Schaft,D.W.J., Hargittai,B., Haseman,J., Griffioen,A.W., Mayo,K.H. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Letters 2003; 194(-1-):55-66. >>> Anginex; PBS; albumin, human serum; SC; Mice (nude); 2004; 28 days; Dose-response; cancer (ovarian); angiogenesis inhibitor; comparison of once or twice daily injections; alginate beads and minipumps; "Of the three administrative routes used (daily loco-regional bolus injections, continuous systemic delivery via osmotic mini-pumps and suspension in alginate beads implanted subcutaneously), continuous systemic administration of the peptide worked best." (p. 63).

P6532 Sun,X., Yang,Z., Li,S., Tan,Y., Zhang,N., Wang,X., Yagi,S., Yoshioka,T., Takimoto,A., Mitsushima,K., Suginaka,A., Frenkel,E.P., Hoffman,R.M. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation. Cancer Research 2003; 63(-23-):8377-8383. >>> PLP; SC; Mice (nude); 2001; 1 week; PLP plasma levels taken; cancer; PLP is a pyridoxal 5'-phosphate enzyme.

P6231 Masunaga,S., Ono,K., Takahashi,A., Ohnishi,K., Ohnishi,T., Suzuki,M., Nagata,K., Kinashi,Y., Nagasawa,H., Uto,Y., Hori,H. Usefulness of combined treatment with mild temperature hyperthermia and/or tirapazamine in the treatment of solid tumors: its independence of p53 status. CANCER SCIENCE 2003; 94(-1-):125-133. >>> Uridine, bromodeoxy-; Saline, physiological; SC; Mice (nude); 2001; 7 days; Controls received no treatment; cancer (squamous cell carcinoma).

P6050 Martin,T.A., Parr,C., Davies,G., Watkins,G., Lane,J., Matsumoto,K., Nakamura,T., Mansel,R.E., Jiang,W.G. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 2003; 24(-8-):1317-1323. >>> NK4; Hepatocyte factor/scatter factor; BSA; SC; Mice (nude); 2004; 4 weeks; Controls received mp w/ vehicle; cancer (breast); peptides; NK4 is a hepatocyte growth factor/scatter factor (HGF/SF) antagonist; angiogenesis research.

P6042 Terunuma,A., Jackson,K.L., Kapoor,V., Telford,W.G., Vogel,J.C. Side population keratinocytes resembling bone marrow side population stem cells are distinct from label-retaining keratinocyte stem cells. Journal of Investigative Dermatology 2003; 121(-5-):1095-1103. >>> Uridine, bromodeoxy-; SC; Mice (nude); 1002; 6 weeks; Pumps replaced every 2 weeks; multiple pumps per animal (2); labeling of skin grafts.

P6000 Dings,R.P.M., Yokoyama,Y., Ramakrishnan,S., Griffioen,A.W., Mayo,K.H. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Research 2003; 63(-2-):382-385. >>> Anginex; Bpep28; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; dose-response (fig.1, p. 383); cancer (ovarian); peptides; anginex is a potent angiogenesis inhibitor; Bpep28 is a control peptide without antiangiogenic activity.

P5999 Mayo,K.H., Dings,R.P.M., Flader,C., Nesmelova,I., Hargittai,B., van der Schaft,D.W.J., van Eijk,L.I., Walek,D., Haseman,J., Hoye,T.R., Griffioen,A.W. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. Journal of Biological Chemistry 2003; 278(-46-):45746-45752. >>> Anginex; 6DBF7; PBS; albumin, human serum; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer (ovarian); peptides; angiogenesis inhibitors.

P5997 Kuroiwa,M., Takeuchi,T., Lee,J.H., Yoshizawa,J., Hirato,J., Kaneko,S., Choi,S.H., Suzuki,N., Ikeda,H., Tsuchida,Y. Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. Journal of Pediatric Surgery 2003; 38(-10-):1499-1505. >>> Endostatin, recomb. human; Saline; SC; Mice (nude); 1003D; 3 days; Controls received 3 mp w/ vehicle; comparison of SC injections vs. mp; no stress (see p. 1501); cancer (neuroblastoma); angiogenesis inhibitor; multiple pumps per animal (3); picture of nude mouse w/3 pumps (fig.1; p. 1500); "The set of 3 osmotic pumps was retained successfully in the subcutaneous tissue of the treated and control animals throughout the experiment, no decrease in body weight was observed in either group." (p. 1501).

P5947 Strock,C.J., Park,J.I., Rosen,M., Dionne,C., Ruggeri,B., Jones-Bolin,S., Denmeade,S.R., Ball,D.W., Nelkin,B.D. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Research 2003; 63(-17-):5559-5563. >>> CEP-2563; Solutol; SC; Mice (nude); 2002; 14 days; Cancer (thyroid); CEP-2563 is an indolocarbazole derivative; it is a pro-drug of CEP-751; solutol is PEG 660 (12-hydroxy-stearate).

P5946 Zilberberg,L., Shinkaruk,S., Lequin,O., Rousseau,B., Hagedorn,M., Costa,F., Caronzolo,D., Balke,M., Canron,X., Convert,O., Lain,G., Gionnet,K., Goncalves,M., Bayle,M., Bello,L., Chassaing,G., Deleris,G., Bikfalvi,A. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. Journal of Biological Chemistry 2003; 278(-37-):35564-35573. >>> CBO-p11; PBS; SC; Mice (nude); 2004; 28,58 days; Controls received mp w/ vehicle; long-term study; pumps replaced every 28 days for the long-term study; cancer (glioma); CBO-p11 is a cyclo-VEGI inhibitor; angiogenesis inhibitor.

P5940 Davies,G., Mason,M.D., Martin,T.A., Parr,C., Watkins,G., Lane,J., Matsumoto,K., Nakamura,T., Jiang,W.G. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostat e tumor growth and angiogenesis in vivo. International Journal of Cancer 2003; 106(-3-):348-354. >>> Hepatocyte growth factor; NK4; BSA; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer (prostate); NK4 (HGF/SF antagonist) is recomb. human.

P5927 Shao,T.C., Li,H.L., Eid,W., Ittmann,M., Unni,E., Cunningham,G.R. In vivo preservation of steroid specificity in CWR22 xenografts having a mutated androgen receptor. PROSTATE 2003; 57(-1-):1-7. >>> Testosterone; estradiol; progesterone; flutamide; Cylodextrin, 2-beta-hydroxypropl; SC; Mice (nude); 2004; 4 weeks; Replacement therapy (castration); cancer (prostate); CWR22 xenograft used; flutamide is an anti-androgen; animal info (5-6 week old, nude ,ORX).

P5848 Gariboldi,M.B., Ravizza,R., Petterino,C., Castagnaro,M., Finocchiaro,G., Monti,E. Study of in vitro and in vivo effects of the piperidine nitroxide Tempol - a potential new therapeutic agent for gliomas. European Journal of Cancer 2003; 39(-6-):829-837. >>> Tempol; Saline, sterile; SC; Mice (nude); 2002; 14 days; Controls received mp w/ vehicle; functionality of mp verified by plasma levels; comparison of IP injections vs. mp; adverse reaction: (see pg. 835) precipitation in pump; cancer (glioma); antioxidant; tempol (TPL) or (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxy) or superoxide dismutase, mimetic is a stable nitroxide free radical; "375 mg/ml concentration was highest achievable TPL concentration, when this limit was exceeded, TPL precipitation occurred, impairing drug flow from the pump...".

P5726 Eder,I.E, Hoffmann,J, Rogatsch,H, Schafer,G, Zopf,D, Bartsch,G, Klocker,H  Cancer Gene Therapy 2003; 9(-2-):117-125. >>> Oligonucleotide, antisense; Water, distilled; SC; Mice (nude); 7 weeks; Controls received mp w/ vehicle; long-term study, pumps replaced every two weeks; no stress (see pg. 122); cancer (prostate); antisense; pumps implanted SC in the vicinity of tumors; ODN w/ specificity to the androgen receptor; "...mice did not show any reaction on the subcutaneously installed ALZET diffusion pumps. These were chosen to guarantee a continuous systemic administration of oligonucleotides, a commonly used method for antisense treatment in vivo." (p 122).

P5710 Sundaram,S., Sea,A., Feldman,S., Strawbridge,R., Hoopes,P.J., Demidenko,E., Binderup,L., Gewirtz,D.A. The combination of a potent vitamin D-3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clinical Cancer Research 2003; 9(-6-):2350-2356. >>> EB 1089; Disodium phosphate dihydrate; phosphate dihydrate; solutol HS-15; sodium chloride; sodium dihydrate; sodium; SC; Mice (nude); 1002; 8 days; Controls received mp w/ vehicle; cancer (breast); EB 1089 is a vitamin D analog; also called seocalcitol.

P5603 Fluiter,K., ten Asbroek,A.L.M.A., de Wissel,M.B., Jakobs,M.E., Wissenbach,M., Olsson,H., Olsen,O., Oerum,H., Baas,F. In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. NUCLEIC ACIDS RESEARCH 2003; 31(-3-):953-962. >>> Oligonucleotide, antisense; Saline; SC; Mice (nude); 1002; 14 days; Controls received mp/ w vehicle; dose response (graph p. 959); half-life (p. 956); cancer; peptides; antisense; LNA PO ODN's used.

P5515 Casanova,M.L., Blazquez,C., Martinez-Palacio,J., Villanueva,C., Fernandez-Acenero,M.J., Huffman,J.W., Jorcano,J.L., Guzman,M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J.Clin.Invest 2003; 111(-1-):43-50. >>> JWH-133; WIN-55,212-2; PBS; BSA; SC; Mice (nude); 2002; 11 days; Controls received mp w/ vehicle; cancer; cannabinoid agonists.

R0221 Frydman,B., Basu,H.S  Expert Opin.Ther.Parents 2002; 12(-7-):1035-1046. >>> Doxorubicin, heptapeptide conjugate; Mice (nude); 10 days; Cancer (prostate); ALZET pumps mentioned on pg. 1039.

P7698 Seurin,D., Lassarre,C., Bienvenu,G., Babajko,S. Insulin-like growth factor binding protein-6 inhibits neuroblastoma cell proliferation and tumour development. Eur.J.Cancer 2002/10; 38(-15-):2058-2065. >>> Insulin-like growth factor binding protein-6; glutathione S-transferase; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ GST; dose-response (table 1); comparison of daily IP injections vs. mp; cancer (neuroblastoma); peptides; animal info (female, SP Swiss nude, 6 wk old); "The (tumor developed) delay was not evident in mice injected i.p., possibly because IGFBP-6 is rapidly degraded in the bloodstream." (p. 2063).

P5664 Hagedorn,M., Zilberberg,L., Wilting,J., Canron,X., Carrabba,G., Giussani,C., Pluderi,M., Bello,L., Bikfalvi,A. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Research 2002; 62(-23-):6884-6890. >>> Platelet factor 4 peptides; PBS; CSF/CNS (intratumoral); Mice (nude); 2004; 30 days; Controls received mp w/ vehicle; tissue perfusion (intratumoral); dose-response (p. 6888; fig 6); cancer; peptides; glioma; antiangiogenesis..

P5573 Ghatak,S., Misra,S., Toole,B.P. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. Journal of Biological Chemistry 2002; 277(-41-):38013-38020. >>> Hyaluronan oligosaccharides; PBS; SC; mice (nude); 7, 14 days; controls received mp with vehicle; cancer; hyaluronan is a large polysaccharide anti-tumor compound; 0.5 ul/hr pumps used.

P5505 Aharinejad,S., Abraham,D., Paulus,P., Abri,H., Hofmann,M., Grossschmidt,K., Schafer,R., Stanley,E.R., Hofbauer,R. Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Research 2002; 62(-18-):5317-5324. >>> Oligonucleotide, sense; oligonucleotide, antisense; SC; Mice (scid); mice (nude); 1002; 14 days; Controls received mp w/ Ringer's; cancer; antisense.

P5439 Kawakami,K., Husain,S.R., Kawakami,M., Puri,R.K. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. MOLECULAR MEDICINE 2002; 8(-8-):487-494. >>> Interleukin-13 endotoxin; PBS; IP; Mice (nude); 7 days; Comparison of IV injections vs mp; cancer (head and neck); IL-13 endotoxin, also called IL13-PE38QQR, is composed of IL-13 and a mutated form of a Pseudomonas endotoxin; compared to IV injections, continuous infusion decreased the toxicity and increased the efficacy of IL-13 cytotoxin.

P5383 Lobell,R.B., Liu,D.M., Buser,C.A., Davide,J.P., DePuy,E., Hamilton,K., Koblan,K.S., Lee,Y., Mosser,S., Motzel,S.L., Abbruzzese,J.L., Fuchs,C.S., Rowinsky,E.K., Rubin,E.H., Sharma,S., Deutsch,P.J., Mazina,K.E., Morrison,B.W., Wildonger,L., Yao,S.L., Kohl,N.E. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl : protein transferase and geranylgeranyl : protein transferase type-1. MOLECULAR CANCER THERAPEUTICS 2002; 1(-9-):747-758. >>> Farnesyl:protein transferase inhibitor-I; DMSO; SC; Mice (nude); 2ML2; 7, 14 days; Enzyme inhibitor; cancer.

P5338 Kimata,M., Otani,Y., Kubota,T., Igarashi,N., Yokoyama,T., Wada,N., Yoshimizu,N., Fujii,M., Kameyama,K., Okada,Y., Kumai,K., Kitajima,M. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. Japanese Journal of Cancer Research 2002; 93(-7-):834-841. >>> Oligodeoxynucleotide, antisense; Saline; SC; Mice (nude); 1002; 28 days; Controls received mp w/ vehicle; cancer; phosphorothioate sense and antisense used.

P5048 Chan,D.C., Gera,L., Stewart,J.M., Helfrich,B., Zhao,T.L.M., Feng,W.Y., Chan,K.K., Covey,J.M., Bunn,PA Jr  Clinical Cancer Research 2002; 8(--):1280-1287. >>> CU201; Saline; SC; mice (nude); 32 days; controls received mp w/ vehicle; functionality of mp verified by CU201 plasma levels; half-life (p. 1280) 14.4 min (alpha) or 44.3 hrs (beta); peptides; cancer (lung); study examined numerous routes, including intratumoral injections, ip injections, sc infusion via minipump; bolus iv infusion; "The continuous s.c. infusion by ALZET pumps at 5 mg/kg/day was slightly more effective than the intratumor route." (p. 1283).

P5033 Masunaga,S., Ono,K., Takahashi,A., Ohnishi,T., Kinashi,Y., Takagaki,M. Radiobiological characteristics of solid tumours depending on the p53 status of the tumour cells, with emphasis on the response of intratumour quiescent cells. European Journal of Cancer 2002; 38(--):718-727. >>> Uridine, bromodeoxy-; Saline; SC; mice (nude); 2001; 7 days; cancer; tumor cell proliferation labelling.

P6291 Maeshima,Y., Manfredi,M., Reimer,C., Holthaus,K.A., Hopfer,H., Chandamuri,B.R., Kharbanda,S., Kalluri,R. Identification of the Anti-angiogenic Site within Vascular Basement Membrane-derived Tumstatin. The Journal of Biological Chemistry 2001; 276(-18-):15240-15248. >>> Tumstatin, -5; PBS; SC; Mice (nude); 21 days; Controls received IP vehicle injections; comparison of IP injections vs. mp; cancer (prostate); peptides; anti-angigenic; TUM-5 is the 54-132 amino acid domain.

P4870 Xu,X.L., Kreye,E., Kuo,C.B., Walker,A.M. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice. Cancer Research 2001; 61(--):6098-6104. >>> Prolactin; S179D; SC; mice (nude); 2004; 22-24 days; controls received mp w/ vehicle; functionality of mp verified by plasma prolactin levels; peptides; cancer (prostate); S179D is a prolactin receptor antagonist; wild-type prolactin used..

P8575 Pavco,P.A., Bouhana,K.S., Gallegos,A.M., Agrawal,A., Blanchard,K.S., Grimm,S.L., Jensen,K.L., Andrews,L.E., Wincott,F.E., Pitot,P.A. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000; 6(-5-):2094-2103. >>> Ribozyme, anti-Flt-1; ribozyme, anti-KDR; ribozyme, attenuated; Saline; IV (jugular); SC; Mice; mice (nude); 2002; 14,28 days; Controls received mp w/ vehicle or attenuated control; dose-response (fig. 2); pumps replaced after 18 days; stress/adverse reaction (see pg. 2096);<10% of animals removed from study due to catheter failure or animal not surviving pump implantation; half-life (p. 2100) IV and SC similar; cancer (lung carcinoma, colorectal carcinoma, liver metastasis); animal info (female, C57BL/6, 6-8 weeks old, male, nude, 6-8 weeks old); antiangiogenic, 80% bioavailable after SC administration; targets VEGF receptor mRNA; anti-Flt-1 ribozyme also known as angiozyme.

P4655 Cohen-Jonathan,E, Muschel,R.J, McKenna,W.G, Evans,S.M, Cerniglia,G, Mick,R, Kusewitt,D, Sebti,S.M, Hamilton,A.D, Oliff,A, Kohl,N, Gibbs,J.B, Bernhard,E.J  Radiat.Res. 2000; 154(--):125-132. >>> L-744,832;; DMSO; Water;; SC;; mice (nude);; 3-7 days;; Controls received mp w/ vehicle; cancer; enzyme inhibitor; 50% DMSO used; L-744,832 is a Farnesyltransferase inhibitor.

P4484 Abdaimi,K.E, Dion,N, Papavasiliou,V, Cardinal,P-E, Binderup,L, Goltzman,D, Ste-Marie,L-G, Kremer,R  Cancer Research 2000/8/15; 60(--):4412-4418. >>> EB 1089; Propylene glycol; ethanol; saline; SC; Mice (nude); 2ML4; 4 weeks; Controls received mp w/vehicle; cancer; transplantation; EB 1089 is a vitamin D analog.

R0162 Schally,A.V., Varga,J.L. Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents. Trends Endocrinol Metab 1999/12; 10(-10-):383-391. >>> MZ-4-71; Mice (nude); 4 weeks; Comparison of sc injections vs. mp; cancer; MZ-4-71 is a growth hormone-releasing hormone antagonist; pump use mentioned briefly on p.385.

P4640 Alvarez-Salas,L.M, Arpawong,T.E, Dipaolo,J.A  Antisense&Nucleic Acid Drug Development 1999; 9(--):441-450. >>> Oligodeoxynucleotide, antisense;; Water, deionized;; SC;; mice(nude);; 1002;; 2 weeks;; Controls received mp w/ vehicle; cancer; antisense; mp was implanted SC near the tumor..

P4409 Maoret,J-J, Anini,Y, Rouyer-Fessard,C, Gully,D, Laburthe,M  Int.J.Cancer 1999; 80(--):448-454. >>> Neurotensin; PBS; BSA; SC; Mice (nude); 22 days; Controls received mp w/vehicle; cancer; peptides.

P4401 Skrepnik,N., Zieske,A.W., Bravo,J.C., Gillespie,A.T., Hunt,J.D. Recombinant oncotoxin AR209 (anti-P185erbB-2) diminishes human prostate carcinoma xenografts;. Journal of Urology 1999/3; 161(--):984-989. >>> AR209;; PBS;; SC;; mice (nude);; 2002;; 14 days;; controls received mp with vehicle; comparison of IV injections vs. mp; cancer (prostate); AR209 is a recomb. oncotoxin, also known as OLX-209 or e23(Fu)PE38KDEL.

P4381 Chesney,J., Mitchell,R., Benigni,F., Bacher,M., Spiegel,L., Al-Abed,Y., Han,J.H., Metz,C., Bucala,R. An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: Role in tumor cell glycolysis and the Warburg effect. Proc.Natl.Acad.Sci.USA 1999/3; 96(--):3047-3052. >>> Oligonucleotides, phosphorothioate antisense;; PBS, pyrogen-free;; SC;; mice (nude);; ; controls received mp with vehicle or sense oligo; cancer; antisense;.

P4638 Buchsbaum,D.J., Liu,T., Roberson,P.L., Bright,S, Elliott,D.G, Khazaeli,M.B. Comparison of biodistribution of 131I CC49 mAb in athymic nude mice bearing LS174T colon cancer xenografts following bolus injection or continuous infusion.. Tumor Targeting 1998; 3(--):178-190. >>> Antibody, monoclonal, CC49;; Radio-isotopes 131I; PBS; Albumin, human serum;; SC; IP;; mice (nude);; 2001;; 7 days;; controls received mp w/vehicle; functionality verified by (incorrectly) weighing pumps at the end of infusion; comparison of bolus IP injections vs. mp; cancer;.

P4615 Dondi,D, Moretti,R.M, Marelli,M.M, Pratesi,G., Polizzi,D, Milani,M, Motta,M, Limonta,P  Int.J.Cancer 1998; 76(--):506-511. >>> Luteinizing HRH agonist;; Propylene glycol; Water;; SC;; mice (nude);; 2002;; 14 days;; controls received mp/vehicle; cancer (prostate); Zoladex was the LHRH agonist used;.

P4528 Maruno,K, Absood,A, Said,S.I  Proc.Natl.Acad.Sci. 1998/11; 95(--):14373-14378. >>> Vasoactive intestinal peptide; forskolin; PBS; DMSO; SC; Mice (nude); 2002; 8 weeks; Controls received mp w/PBS; dose-response (pg. 14376-14377); long-term study, pumps replaced after 2 weeks; cancer (lung); multiple pumps per animal (2) in some animals; "For systemic delivery of peptides in vivo, constant infusion by osmotic pumps increases efficacy and reduces side effects relative to bolus injection." (p. 14377)..

P4032 Chiba,Y., Kubota,T., Watanabe,M., Matsuzaki,S.W., Otani,Y., Teramoto,T., Matsumoto,Y., Koya,K., Kitajima,M. MKT-077, localized lipophilic cation: antitumor activity against human tumor xenografts serially transplanted into nude mice. Anticancer Res. 1998; 18(--):1047-1052. >>> MKT-077; Water, sterile; SC; mice (nude); 14 days; agent formerly called FJ776; cancer.

P4020 Song,S., Suzuki,H., Terasaki,T., Lemaire,M., Sugiyama,Y. Modulation of the tumor disposition of vinca alkaloids by PSC 833 in vitro and in vivo. J.Pharmacol.Exp.Ther. 1998; 287(--):963-968. >>> PSC 833; Cremophor; Ethanol; IP; mice (nude); 1007D; 7 days; controls received mp w/vehicle or saline; functionality of mp verified by plasma levels (p. 967); dose-response (p. 966); PSC 833 is a cyclosporine A analog with no immunosuppressive action; Konsentrat Zuer infusion vehicle used (cremophor/EtOH=65/35 v/v); cancer.

P3717 Yang,D., Kuan,C.-T., Payne,J., Kihara,A., Murray,A., Wang,L.-M., Alimandi,M., Pierce,J.H., Pastan,J.H., Lippman,M.E. Recombinant heregulin-pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. Clin.Cancer Res. 1998; 4(--):993-1004. >>> Heregulin, B1, PE38KDEL; PBS; Albumin, human serum; IP; mice (nude); 1007D; 7 days; dose-response; comparison of IV&intratumoral injections vs. mp; stability verified by in vitro assay; cancer; toxicology; peptides; PE38KDEL is Pseudomonas exotoxin sequence; agent is a recomb. chimeric toxin; mp model was 1007D, not '107'.

P4525 Iversen,P.O, Lewis,I.D, Turczynowicz,S, Hasle,H., Niemeyer,C, Schmiegelow,K, Bastiras,S, Biondi,A, Hughes,T.P, Lopez,A.F  Blood 1997/12/15; 90(-12-):4910-4917. >>> Colony-stimulating factor, GM; Antibody, monoclonal anti-TNFa;; Saline, isotonic;; IP;; mice (nude);; 4 weeks;; controls received mp w/vehicle; functionality of mp verified by plasma levels; immunology; peptides;.

P3921 Benedetti,S., Dimeco,F., Pollo,B., Cirenei,B., Colombo,B.M., Bruzzone,M.G., Cattaneo,E., Vescovi,A., Didonato,S., Colombo,M.P., Finocchiaro,G. Limited efficacy of the hsv-tk/gcv system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Human Gene Therapy 1997; 8(--):1345-1353. >>> Ganciclovir; Water; rat; mice (nude); 2002; 2ML2; 2 weeks; comparison of IP injections vs. mp; cancer; gene therapy.

P3919 Roberson,P.L., Dudek,S., Buchsbaum,D.J. Dosimetric comparison of bolus and continuous injections of CC49 monoclonal antibody in a colon cancer xenograft model. Cancer 1997; 80(--):2567-2575. >>> Antibody, monoclonal, CC49; PBS; 131I tracer; Albumin, human serum; IP; mice (nude); 2001; 7 days; comparison of IP bolus injections vs. mp; cancer; immunology.

P3909 Joschko,M.A., Webster,L.K., Bishop,J.F., Yuen,K., Olver,I.N., Narayan,K.N., Ball,D.L. Radioenhancement by cisplatin with accelerated fractionated radiotherapy in a human tumour xenograft. Cancer Chemother.Pharmacol. 1997; 40(--):534-539. >>> Cisplatin; Saline; SC; mice (nude); 2002; 13 days; comparison of IP injections vs. mp; no stress (see pg. 536); cancer; toxicology.

P3835 Adam,L., Crepin,M., Israel,L. Tumor growth inhibition, apoptosis, and bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination. Cancer Res. 1997; 57(--):1023-1029. >>> Sodium phenylacetate; SC; mice (nude); 2 weeks; cancer.

P3809 Mata,J.E., Joshi,S.S., Palen,B., Pirruccello,S.J., Jackson,J.D., Elias,N., Page,T.J., Medlin,K.L., Iversen,P.L. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of burkitt's lymphoma cells in vitro and in vivo. Toxicol.Appl.Pharmacol. 1997; 144(--):189-197. >>> Oligodeoxynucleotide, phosphorothioate; PBS; Fluorescein, 5-carboxy; SC; mice (nude); 2002; 7,14 days; controls received mp w/scrambled sequence or saline; no stress (see pg. 194); stability verified by FITC labeled oligo; cancer.

P3577 Sharma,A., Glaves,D., Porter,C.W., Raghavan,D., Bernacki,R.J. Antitumor efficacy of N1,N11-diethylnorspermine on a human bladder tumor xenograft in nude athymic mice. Clin.Cancer Res. 1997; 3(--):1239-1244. >>> DENSPM; PBS, sterile; SC; mice (nude); 2001; 5 days; controls received mp w/ PBS; pump implanted on flank, opposite tumor; cancer.

P3637 Kinuya,S., Yokoyama,K., Konishi,S., Tonami,N., Hisada,K. Effect of induced hypertension with angiotensin II infusion on biodistribution of 111In-labeled monoclonal antibody. Nuclear Medicine&Biology 1996; 23(--):137-140. >>> Angiotensin II; Saline; SC; mice (nude); 1003D; no duration posted; controls received mp w/ saline; cancer; immunology; peptides.

P3610 Fisher,W.E., Muscarella,P., O'Dorisio,T.M., O'Dorisio,M.S., Kim,J.A., Doran,T.A., Sabourin,C.L., Schirmer,W.J. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery 1996; 120(--):234-241. >>> Octreotide; Saline; SC; mice (nude); 2002; 36 days; controls received mp w/ saline; long-term study, pumps replaced every two weeks; cancer; pumps implanted on flank opposite tumor.

P3560 Pratesi,G., Cervi,S., Balsari,A., Bondiolotti,G., Vicentini,L.M. Effect of serotonin and nicotine on the growth of a human small cell lung cancer xenograft. Anticancer Res. 1996; 16(--):3615-3620. >>> Serotonin; Nicotine; Water; Acetic acid; SC; mice (nude); 2002; no duration posted; controls received mp w/ vehicle; cancer (lung).

P3414 Teramoto,T., Onda,M., Tokunaga,A., Asano,G. Inhibitory effect of anti-epidermal growth factor receptor antibody on a human gastric cancer. Cancer 1996; 77(--):1639-1645. >>> Antibody, anti-EGF receptor monoclonal; PBS; SC; mice (nude); 2002; 14 days; controls received mp w/PBS; comparison of IP injections vs. mp; cancer.

P3412 Rubenstein,M., Mirochnik,Y., Chou,P., Guinan,P. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J.Surg.Oncology 1996; 62(--):194-200. >>> Oligonucleotide, antisense; Tris HCl; EDTA; SC; mice (nude); 1007D; 7 days; comparison of intratumoral injections vs. mp; cancer (prostate); antisense; pump contained both oligos; "Although direct inoculation of tumors was effective, systemic administration of oligos using ... pumps appears to have a better response rate." (p. 199); oligos were directed against mRNAs encoding transforming growth factor-alpha and epidermal growth factor receptor.

P3380 Kinsella,T.J., Glennon,M.C., Kunugi,K.A., Linstrom,M.J. In vivo modulation of iododeoxyuridine metabolism and incorporation into cellular DNA by 5'-amino-5'-deoxythymidine in normal mouse tissues and two human colon cancer xenografts. Clin.Cancer Res. 1996; 2(--):981-989. >>> Uridine, iododeoxy-; Thymidine, 5'-amino-5'-deoxy-; NaOH; SC; mice (nude); 2001; 6 days; controls received mp w/NaOH; 6 day stability verified by uv spectrophotometry p.983; cancer; toxicology; 1-2 mps used per animal; agents given singly&together.

P4215 Pinski,J., Schally,A.V., Groot,K., Halmos,G., Szepeshazi,K., Zarandi,M., Armatis,P. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J.Natl.Cancer Inst. 1995; 87(-23-):1787-1794. >>> MZ-4-71; Propylene glycol; Water; SC; mice (nude); 2002; 3,4 weeks; Controls received mp w/saline; comparison of s.c. injections vs. mp; pumps replaced after 2 weeks; GH-RH inhibitor; cancer.

P4212 Ramage,A.D., Langdon,S.P., Ritchie,A.A., Burns,D.J., Miller,W.R. Growth inhibition by 8-chloro cyclic AMP of human HT29 colorectal and ZR-75-1 breast carcinoma xenografts is associated with selective modulation of protein kinase A isoenzymes. Eur.J.Cancer 1995; 31A(-6-):969-973. >>> Cyclic AMP, 8-Cl-; Water; mice (nude); 7 days; controls received mp w/vehicle; cyclic AMP analog; cancer.

P4107 Benhar,I., Reiter,Y., Pai,L.H., Pastan,I. Administration of disulfide-stabilized FV-immunotoxins B1(dSFV)-PE38 and B3(dSFV)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int.J.Cancer 1995; 62(--):351-355. >>> B1(dSFV)-PE38; B3(dSFV)-PE38; PBS; IP; mice (nude); 1007D; 6 days; controls received mp w/vehicle; functionality of mp verified by immunotoxin blood levels; comparison of IV bolus injections vs. mp; stability verified by 37 C incubation up to 14 days and assay; cancer; immunology; agents are dSFV-immunotoxins; "These results show that continuous infusion results in a significantly larger...therapeutic index, and...may be a more effective method delivering the dSFV-immunotoxins" (p. 355); good stability data.

P4086 Kitagawa,Y., Ueda,M., Ando,N., Ozawa,S., Kitajima,M. Effect of endogenous and exogenous EGF on the growth of EGF receptor-hyperproducing human squamous cell carcinoma implanted in nude mice. Br.J.Cancer 1995; 72(--):865-868. >>> Epidermal growth factor, mouse; Saline; SC; mice (nude); 9 days; controls received mp w/vehicle; functionality of mp verified by plasma levels; replacement therapy (sialoadenectomy); cancer; peptides.

P4082 Liu,C.D., Slice,L.W., Balasubramaniam,A., Walsh,J.H., Newton,T.R., Saxton,R.E., McFadden,D.W. Y2 receptors decrease human pancreatic cancer growth and intracellular cyclic adenosine monophosphate levels. Surgery 1995; 118(--):229-236. >>> Peptide YY; BIM-43004-1; mice (nude); 2,3,4 weeks; controls received mp w/saline; cancer; peptide YY is an enteric hormone; BIM-43004-1 is a modified PYY (22-36) Y2 receptor agonist; peptides.

P3436 Igarashi,K., Koga,K., He,Y., Shimogori,T., Ekimoto,H., Kashiwagi,K., Shirahata,A. Inhibition of the growth of various human and mouse tumor cells by 1,15-Bis(ethylamino)-4,8,12-triazapentadecane. Cancer Res. 1995; 55(--):2615-2619. >>> BE3333; IP; mice (nude); 1007D; no duration posted; comparison of iv&ip injections vs. oral delivery vs. mp; BE3333 is 1,5-bis(ethylamino)-4,8,12-triazapentadecane; cancer.

P3386 Paschke,R., Eck,T., Herfurth,J., Usadel,K.-H. Stimulation of proliferation and inhibition of function of xenotransplanted human thyroid tissue by epidermal growth factor. J.Endocrinol.Invest. 1995; 18(--):359-363. >>> Epidermal growth factor; SC; mice (nude); 7 days; comparison of IP injections vs. mp; half-life (p.362); peptides.

P3102 Bernacki,R.J., Oberman,E.J., Seweryniak,K.E., Atwood,A., Bergeron,R.J., Porter,C.W. Preclinical antitumor efficacy of the polyamine analogue N1,N11-diethylnorspermine administered by multiple injection or continuous infusion. Clin.Cancer Res. 1995; 1(--):847-857. >>> DENSPM; SC; mice (nude); 2001; 4 days; controls received mp with saline; stress/adverse reaction: severe toxicity (early death or weight loss) occurred in highest DENSPM infusion (360 mg/kg/day for 4 days); cancer; DENSPM is N,N-diethylnorspermine, an analogue of the polyamine spermine.

P3048 Adam,L., Crepin,M., Savin,C., Israel,L. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Cancer Res. 1995; 55(--):5156-5160. >>> Sodium phenylacetate; SC; mice (nude); 2002; 2 weeks; cancer.

P2871 Manetta,A., Gamboa-Vujicic,G., Paredes,P., Emma,D., Liao,S., Leong,L., Asch,B., Schally,A. Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75). Fertility and Sterility 1995; 62(-2-):282-287. >>> SB-75; Mannitol; Saline; SC; mice (nude); 2002; no duration posted; controls received mp with vehicles; cancer; SB-75 is also known as Cetrorelix and is an LHRH antagonist.

P2823 Popnikolov,N.K., Yang,J., Guzman,R.C., Swanson,S.M., Thordarson,G., Collins,G., Talamantes,F., Nandi,S. In vivo growth stimulation of collagen gel embedded normal human and mouse primary mammary epithelial cells. J.Cell.Physiology 1995; 163(--):51-60. >>> Epidermal growth factor; Cortisol; Toxin, cholera; Uridine, bromodeoxy-;; Medium 199;; SC; gel;; mice (nude);; 1003D;; 3 days;; peptides; "tissue perfusion" -- gel containing human mammary epithelial cells was infused; estradiol, progesterone, and cholesterol combinations administered via silastic capsules EGF cholera toxin and hydrocortisone stimulated DNA synthesis substantially with the greatest response seen in the gel proximal to the pump: local delivery appears to be superior to injection;.

P2643 Bokemeyer,C., Ludwig,E., Reile,D., Harstrick,A., Poliwoda,H., Schmoll,H.J. Antitumor activity and toxicity of continuous infusion versus bolus administration of bleomycin in two heterotransplanted human testicular cancer cell lines. Oncology Reports 1995; 2(--):161-165. >>> Bleomycin; SC; mice (nude); 7 days; Antibiotic; comparison of bolus ip injections vs. mp; cancer; toxicology; ". . .bolus application of bleomycin is at least as active as continuous infusion. . .".

P3210 Kihara,A., Pastan,I. Small chimeric toxins containing only transforming growth factor a and domain III of pseudomonas exotoxin with good antitumor activity in mice. Cancer Res. 1994; 54(--):5154-5159. >>> Toxin, transforming growth factor-a chimeric-; PBS; Albumin, human serum; IP; mice (nude); 7 days; controls received mp with PBS; stability of TGFa chimeric toxins found to be 80-100% after 7 days at 37 degrees; cancer.

P2917 Rodriguez,R., Ritter,M.A., Fowler,J.F., Kinsella,T.J. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int.J.Radiat.Oncol.Biol.Phys. 1994; 29(-1-):105-113. >>> Uridine, iododeoxy-; NaOH; SC; mice (nude); 2001; 1-7 days; controls received mp with vehicle; stability verified for > 7 days; toxicology; half-life; no stress: no tissue damage near pumps.

P2913 Malaker,K., Hurwitz,S.J., Bump,E.A., Griffith,O.W., Lai,L.L., Riese,N., Coleman,C.N. Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine. Int.J.Radiat.Oncol.Biol.Phys. 1994; 29(-2-):407-412. >>> Sulfoximine, L,S-buthionine; SC; mice (nude); no duration posted; agent is a glutathione depletor; cancer.

P2912 Okuda,T., Onda,M., Tokunaga,A., Sugisaki,Y. Stimulatory effect of EGF and inhibitory effect of sialoadenectomy on growth of an EGF receptor-hyperproducing human gastric cancer xenograft in nude mice. Jpn.J.Surg. 1994; 24(--):725-733. >>> Epidermal growth factor; PBS; SC; mice (nude); 2002; no duration posted; controls received mp with PBS; dose response; cancer; peptides; tissue perfusion (tumor); human EGF used.

P2866 Remmenga,S.W, Colcher,D., Gansow,O., Pippen,C.G., Raubitschek,A. Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monoclonal antibody therapy of a human tumor xenograft. Gynecologic Oncology 1994; 55(--):115-122. >>> Uridine, fluorodeoxy-; IP; mice (nude); 1003D; no duration posted; controls received mp wth saline; cancer.

P2788 Naito,K., Kanbayashi,N., Nakajima,S., Murai,T., Arakawa,K., Nishimura,S., Okuyama,A. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int.J.Cancer 1994; 58(--):730-735. >>> BE16627B; Doxorubicin HCl; DMSO; Ethylene glycol; SC; mice (nude); 2001; 2002; 3 weeks, 18 days; controls received vehicle or no treatment; pumps replaced; stress/ adverse reaction: skin inflammation and necrosis around delivery site in mice treated with Adriamycin (pg. 733); BE166278B animals were fine; stability verified for 18 days by assay; cancer; enzyme inhibitor; BE16627B is a metalloproteinase inhibitor; 2002 replaced w/ 2001 after 20 days; adriamycin is doxorubicin HCl.

P2590 Arteaga,C.L., Hurd,S.D., Dugger,T.C., Winnier,A.R., Robertson,J.B. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor a-Pseudomonas exotoxin 40 fusion protein. Cancer Res. 1994; 54(--):4703-4709. >>> Transforming growth factor-a-dcys-PE40; IP; mice (nude); 7 days; controls received mp w/ PBS; stability assessed; 50% cytotoxic potency lost by day 8; cancer; toxicology; peptides; TGF-a-dcys-PE40 used.

P2583 Phillips,P.C., Levow,C., Catterall,M., Colvin,O.M., Pastan,I., Brem,H. Transforming growth factor-a--Pseudomonas exotoxin fusion protein (TGF-a-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice. Cancer Res. 1994; 54(--):1008-1015. >>> Transforming growth factor-a-PE38; Albumin, human serum; Sodium chloride; IP; mice (nude); 7 days; comparison of intracranial injections vs. mp; 7 day stability at 37 degrees verified previously; good methods (pg. 1014(45)); TGF-a-PE38 used; cancer.

P2467 Buchsbaum,D.J., Khazaeli,M.B., Davis,M.A., Lawrence,T.S. Sensitization of radiolabeled monoclonal antibody therapy using bromodeoxyuridine. Cancer Suppl. 1994; 73(-3-):999-1005. >>> Uridine, bromodeoxy-;; mice (nude);; 4 days;; cancer; BrdU improved the efficacy of radiolabeled monoclonal antibodies;.

P2300 Kukreja,S.C., D'Anza,J.J., Wimbiscus,S.A., Fisher,J.E., McKee,R.L., Caulfield,M.P., Rosenblatt,M. Inactivation by plasma may be responsible for lack of efficacy of parathyroid hormone antagonists in hypercalcemia of malignancy. Endocrinology 1994; 134(-5-):2184-2188. >>> Parathyroid hormone antagonist; Acetic acid; Albumin, bovine serum; Cysteine; Saline; SC; mice (nude); 2001; 48 hours; cancer; peptides; iv infusion vs. sc.

P2291 Lawrence,T.S., Davis,M.A., Stetson,P.L., Maybaum,J., Ensminger,W.D. Kinetics of bromodeoxyuridine elimination from human colon cancer cells in vitro and in vivo. Cancer Res. 1994; 54(--):2964-2968. >>> Uridine, bromodeoxy-; Uridine, fluorodeoxy-;; SC;; mice (nude);; 4, 14 days;; dose-response (table, p. 2965); pumps replaced after 7 days; cancer;.

P3163 Huber,B.E., Austin,E.A., Good,S.S., Knick,V.C., Tibbels,S., Richards,C.A. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 1993; 53(--):4619-4626. >>> Fluorocytosine, 5-; IP; mice (nude); 2001; 2002; 7 days; functionality of mp verified by plasma levels; comparison of ip injections&tail vein infusion vs. mp; no stress (see pg. 4622); cancer; toxicology; "plasma half-life of FCyt was approximately 40 min. . ."; use of mp produced no overt toxicity or weight loss; FCyt is a prodrug; pump models not explicitly stated.

P2948 Curfs,J.H.A.J., van der Meide,P.H., Billiau,A., Meuwissen,J.H.E.Th., Eling,W.M.C. Plasmodium berghei: recombinant interferon-y and the development of parasitemia and cerebral lesions in malaria-infected mice. Exp.Parasitology 1993; 77(--):212-223. >>> Interferon-gamma; Saline, isotonic; IP; mice; mice (nude); 2002; no duration posted; controls were untreated, or treated but uninfected; ". . .daily injection of a bolus of 105 units of IFN-gamma is not lethal, whereas even a lower daily total dose of 2.5 x 104 units of IFN-gamma administered by continuous release is lethally toxic."; only continuous delivery was able to prevent development of cerebral malaria; comparison of ip injections vs. mp; recomb. rat IFN-gamma.

P2455 Higgins,K.A., Perez,J.R., Coleman,T.A., Dorshkind,K., McComas,W.A., Sarmiento,U.M., Rosen,C.A., Narayanan,R. Antisense inhibition of the p65 subunit of NF-kB blocks tumorigenicity and causes tumor regression. Proc.Natl.Acad.Sci. 1993; 90(--):9901-9905. >>> Oligonucleotide, antisense; mice (nude); no duration posted; cancer.

P2259 Everard,M.J., Macaulay,V.M., Millar,J.L., Smith,I.E. [D-Arg1, D-Phe5, D-Trp7,9, Leu 11] substance P inhibits the growth of human small cell lung cancer xenografts in vivo. Eur.J.Cancer 1993; 29A(-10-):1450-1453. >>> Substance P, [D-Arg1, D-Phe5, D-trp7,9, Leu11]-; PBS; SC; mice (nude); 1007D; 14 days; controls received mp w/PBS; functionality of mp verified by HPLC quantitation of residual volume; comparison of ip injections vs mp; pumps replaced after 7 days; stability verified for 14 days by in vitro testing at 37C; mp placed near tumor; cancer (lung).

R0126 Wickstrom,E  Tibtech 1992; 10(--):281-287. >>> Oligonucleotide, antisense; SC; mice (nude); no duration posted; "In order to achieve normal antisense DNA inhibition of N-myc gene expression..., it was found necessary to administer the normal oligomers by continuous perfusion from a microosmotic pump..." (p. 285); cancer; antisense.

P3208 Lawrence,T.S., Davis,M.A., Maybaum,J., Mukhopadhyay,S.K., Stetson,P.L., Normolle,D.P., McKeever,P.E., Ensminger,W.D. The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer. Cancer Res. 1992; 52(--):3698-3704. >>> Uridine, bromodeoxy-; Uridine, fluorodeoxy-; mice (nude); 4-14 days; pumps replaced after 1 week; stability of Brdu was 80% after 1 week at 37 degrees; cancer; toxicology; Brdu+/-fdUrd infused.

P2626 Langdon,S., Sethi,T., Ritchie,A., Muir,M., Smyth,J., Rozengurt,E. Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res. 1992; 52(--):4554-4557. >>> Substance P, [D-Arg1, D-Phe5, D-trp7,9, Leu11]-; Substance P(6-11), [Arg6, D-Trp7,9, MePhe8]-; Water, sterile; SC; mice (nude); 1007D; 7 days; controls received mp w/ water; comparison of ip injections vs. mp; cancer (lung); toxicology; peptides; pump implanted in flank contralateral to tumor; higher dose, with less lethality, could be given via pump.

P2120 Weckbecker,G., Tolcsvai,L., Liu,R., Bruns,C. Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995). Metabolism 1992; 41(-9-):99-103. >>> Octreotide; Saline; SC; mice (nude); 2 weeks; controls received pumps with vehicle only; cancer; also called SMS 201-995.

P2106 Weckbecker,G., Liu,R., Tolcsvai,L., Bruns,C. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res. 1992; 52(--):4973-4978. >>> Octreotide; mice (nude); 14 days; half-life (p. 4973); cancer; also called SMS 201-995.

P2096 Redwood,S.M., Liu,B.C.S., Weiss,R.E., Hodge,D.E., Droller,M.J. Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer 1992; 69(-5-):1212-1219. >>> E-64; PBS; IV (jugular); mice (nude); no duration posted; cancer; immunology; enzyme inhibitor (cysteine protease).

P3165 Lawrence,T.S., Davis,M.A., McKeever,P.E., Maybaum,J., Stetson,P.L., Normolle,D.P., Ensminger,W.D. Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo. Cancer Res. 1991; 51(--):3900-3905. >>> Uridine, iododeoxy-; Uridine, fluorodeoxy-; HCO3; Carbonate buffer; SC; mice (nude); 2001; 4-14 days; pumps replaced after one week; stability of IdUrd was 80% after 1 week at 37 degrees; cancer; toxicology; IdUrd given with and without FdUrd; multiple pumps per animal (1-2).

P2052 Smeds,S., Jortso,E., Tegler,L. Thyroid epithelial cell proliferation in xenotransplanted human toxic nodular goitre is increased by Graves' IgG. Acta Endocrinol.(Copenh) 1991; 125(--):416-419. >>> Thymidine; 3H tracer; Radio-isotopes; IP; mice (nude); 2001; 4,12 days; toxicology.

P2051 Smeds,S., Walz,T., Blomquist,L., Larsson,S.-E. Cell proliferation rate and tumor volume in human osteosarcoma during exposure to methotrexate. APMIS 1991; 99(--):898-904. >>> Thymidine; 3H tracer; Radio-isotopes; IP; mice (nude); 2001; 7 days; cancer.

P1937 Radulovic,S., Miller,G., Schally,A.V. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res. 1991; 51(--):6006-6009. >>> RC-3095; Propylene glycol; Water; SC; mice (nude); 2002; 4 weeks; comparison of sc injections vs. mp; pumps replaced after 2 weeks; bombesin antagonist; cancer.

P1913 Siegall,C.B., Kreitman,R.J., FitzGerald,D.J., Pastan,I. Antitumor effects of interleukin-6-pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice. Cancer Res. 1991; 51(--):2831-2836. >>> Interleukin-6, PE66; NAD+; PBS; IP; mice (nude); 1007D; 7 days; functionality of mp verified by serum levels; cancer; immunology; cytotoxicity; stability information given for 7 days at 37C.

P1905 Redding,T.W., Schally,A.V. Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists. J.Endocrinol. 1990; 126(--):309-315. >>> SB-30; SB-75; Propylene glycol; Water; Mice (nude); 2002; 28-30 days; Comparison of bid sc injections vs. mp; pumps replaced after 2 weeks; Luteinizing HRH antagonists.

P1679 Watson,S.A., Durrant,L.G., Morris,D.L. The effect of the E2 prostaglandin enprostil, and the somatostatin analogue SMS 201 995, on the growth of a human gastric cell line, MKN45G. Int.J.Cancer 1990; 45(--):90-94. >>> Enprostil; Octreotide; SC; mice (nude); 2001; 7 days; dose-response (graphs); emprostil is a synthetic prostaglandin E2, SMS 201 995 is a somatostatin analogue; cancer.

P1639 Dennis,J.W., Koch,K., Yousefi,S., VanderElst,I. Growth inhibition of human melanoma tumor xenografts in athymic nude mice by swainsonine. Cancer Res. 1990; 50(--):1867-. >>> Swainsonine; Saline; SC; mice (nude); 2002; 6 weeks; dose-response; long-term study, pump replaced every 2 weeks; cancer.

P1631 Szende,B., Redding,T.W., Schally,A.V. Suppression of meiosis of male germ cells by an antagonist of luteinizing hormone-releasing hormone. Proc.Natl.Acad.Sci. 1990; 87(--):901-903. >>> Luteinizing HRH antagonist; Propylene glycol; Water; SC; mice (nude); 2002; 30 days; comparison of SC injections vs. mp; pump replaced at 2 weeks; states mp is standard for continuous admin..

P1545 Kahl,S.B., Joel,D.D., Nawrocky,M.M., Micca,P.L., Tran,K.P., Finkel,G.C., Slatkin,D.N. Uptake of a nido-carboranylporphyrin by human glioma xenografts in athymic nude mice and by syngeneic ovarian carcinomas in immunocompetent mice. Proc Natl Acad Sci U S A. 1990; 87(-18-):7265-7269. >>> Tetraphenylporphyrin, boronated; Tetraphenylporphyrin sulfonate; Sodium carbonate; water; cremophor; SC; IP;; Mice (nude); 1003D; 2001; 1701; 3 or 7 days; Cancer (glioma); one 2001 pump implanted IP and two 1701 pumps implanted SC in some animals; BTPP; 1003D pumps implanted in nude mice; some nude mice implanted IP w/ 4 or 5 1003D pumps; TTPS dissolved in NaHCO3/ cremophor and delivered IP via 4 1003D pumps..

P1549 Rosol,T.J., Capen,C.C., Horst,R.L. Effects of infusion of human parathyroid hormone-related protein-(1-40) in nude mice: histomorphometric and biochemical investigations. J.Bone and Min.Res. 1988; 3(-6-):699-706. >>> Parathyroid hormone-like protein; Cysteine, l-; Saline; SC; mice (nude); 2001; 2002; 7 days; peptides; hypercalcemia of malignancy factor (1-40).

P1293 Guadagni,F., Schlom,J., Pothen,S., Pestka,S., Greiner,J.W. Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon. Cancer Immunol.Immunother. 1988; 26(--):222-230. >>> Interferon-a, recomb. human; Saline; SC; mice (nude); 2001; 5-13 days; dose-response (graph); half life; comparison of i.m. injections vs. mp infusion; functionality of mp verified by plasma levels; cancer/immunology; peptides.

P1287 Smeds,S., Peter,H.J., Gerber,H., Jortso,E., Lennquist,S., Studer,H. Effects of thyroxine on cell proliferation in human multinodular goiter; a study on growth of thyroid tissue transplanted to nude mice. World J.Surg. 1988; 12(--):241-245. >>> Radio-isotopes; Thymidine; 3H tracer; IP; mice (nude); 2001; 7, 22 days; cancer/immunology; pump replaced weekly.

P1136 Pimm,M.V., Clegg,J.A., Baldwin,R.W. Biodistribution and tumour localization of radiolabelled monoclonal antibody during continuous infusion in nude mice with human tumour xenografts. Eur.J.Cancer Clin.Oncol. 1987; 23(-5-):521-527. >>> Antibody, 791T/36; Immunoglobulin, IgG2b; Radio-isotopes; 125I tracer; 131I tracer; Saline; SC; mice (nude); 2002; 5, 15 days; dose-response; half-life; mp implanted contralaterally to xenografted tumors; concomitant and simult. infusion; 125I tracer used with IgG2b; comparison of sc, iv injections vs. mp infusion; functionality of mp verified by chromatography; stability; cancer.

P1041 Schumm-Draeger,P.-M., Senekowitsch,R., Maul,F.-D., Wenisch,H.J.C., Pickardt,C.R., Usadel,K.H. Evidence of in vivo iodine-induced hyperthyroidism in hyperfunctional autoimmune and autonomous human thyroid tissue xenotransplanted to nude mice. Klin.Wochenschr. 1987; 65(--):197-201. >>> Iodide, potassium; Saline; IP; mice (nude); 2002; 2 weeks; controls received mp w/vehicle; various doses of agent infused.

P7949 Dickson,R.B., McManaway,M.E., Lippman,M.E. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 1986/6/20; 232(-4757-):1540-1543. >>> CME2; SC; Mice (nude); 2001; 2002; 4 weeks; 10,14,25 days; Controls received mp w/ saline; dose-response (fig. 2); pumps replaced every 7 days; cancer (breast); animal info (athymic, Harlan Sprague-Dawley); serum-free conditioned medium from mcf-7 cells treated with 17 beta estradiol (E2), dialysis removed all E2 from CME2 leaving induced growth factors.

P0734 Potter,G.K., Mohamed,A.N., Dracopoli,N.C., Groshen,S.L.B., Shen,R.N., Moore,M.A.S. Action of 1,25-(OH)2D3 in nude mice bearing transplantable human myelogenous leukemic cell lines. Exp.Hematol. 1985; 13(--):722-732. >>> Vitamin D3, 1,25-dihydroxy-; Propylene glycol; SC; mice (nude); 2001; 70 days; mp replaced periodically; long-term study; comparison of various agents iv vs. mp infusion; cancer chemotherapy.

P0504 Heston,W.D.W., Fleischmann,J., Tackett,R.E., Ratliff,T.L. Effects of a-difluoromethylornithine and recombinant interferon-a2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice. Cancer Res. 1984; 44(--):3220-3225. >>> Interferon-a2, recomb. human; SC; mice (nude); 2002; 4 weeks; pump replaced after 2 weeks; immunotherapy; controls received unidentified vehicle in mp; peptides; cancer; recomb. human IF-a2 used.

P0155 Shafie,S.M., Grantham,F.H  J.Natl.Cancer Inst. 1981; 67(-1-):51-56. >>> Prolactin, ovine; Saline; IP; mice (nude); no duration posted; replacement therapy (hypophysectomy); cancer; peptides.

P0046 Herlyn,D.M., Steplewski,Z., Herlyn,M.F., Koprowski,H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 1980; 40(-3-):717-721. >>> Antibody, P3 mouse myeloma; Antibody, ascitic fluid; Antibody, monoclonal carcinoma; IP; SC; mice (nude); 14 days; 1st pump ip for 7 days, replaced sc after 7 days; comparison of ip injection vs. infusion; immunotherapy; cancer.

top of page